Managed Healthcare Connect Presents Details of New PHE RA Study
Christina Vogt with Managed Healthcare Connect recently provided a breakdown and analysis of a new PHE study on the impact of ACPA status on patient costs associated with rheumatoid arthritis.
Published in the Journal of Managed Care Pharmacy, the study demonstrated that patients with rheumatoid arthritis (RA) who are anticitrullinated protein antibodies (ACPA)-positive face a greater economic burden than those who are ACPA-negative.
To read the article, please click here.
To read the study as it appears in the Journal of Managed Care Pharmacy, please click here.
In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.